TPI Presents at the Sixth Annual OneMedForum on January 8-9, 2013 at San Francisco
CHENGDU, China, Jan. 2, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, has been invited to present at the 6th Annual OneMedForum San Francisco 2012 on January 9, 2012, at Sir Francis Drake Hotel at 450 Powell Street, San Francisco, CA 94102. Chief Financial Officer of the Company, Dr. James J. Tong is also invited to the 3rd China Forum panel discussion during the conference.
About OneMedForum
The OneMedForum San Francisco conference, launched in 2008, runs concurrently with J.P. Morgan conference that provides an efficient access to the companies that shape the future of the rapidly changing healthcare landscape with company presentations, panels and workshops for strategic insights and practical benefits.
OneMed China Forum, focusing on the healthcare market in China, is designed to help senior executives shape strategy to approach what is one of the most lucrative and perilous markets in the world. The program will consist of panel sessions that will address critical issues to understanding how Healthcare and life science companies can succeed in China.
Attendees will include institutional investors, senior healthcare executives and life science executives looking for investment opportunities, market insights, licensing opportunities, acquisitions, joint ventures and strategic partnerships.
Additional information can be found via: www.onemedplace.com/forum
About TPI
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. For more information about TPI, please visit: http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please visit: http://www.tianyinpharma.com, or email: ir@tpi.asia
Tel: +86-28-8551-6696 (Chengdu, China)
+86-134-3655-0011 (China)
Address:
Tianyin Pharmaceutical Inc.
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China
SOURCE Tianyin Pharmaceutical Co., Inc.